Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 11/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SSTR1 | P30872 | 4/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20466511 | 0.88 | ALDH1A1 (0.42) | ALDH1A1PDK1PDK2PDK3PDK4 | |
| SCHEMBL23992266 | 0.83 | ALDH1A1 (0.41) | ALDH1A1SIGMAR1EPHX2 | |
| SCHEMBL21940455 | 0.82 | ALDH1A1 (0.42) | ALDH1A1PDK1PDK2PDK3PDK4 | |
| SCHEMBL16072937 | 0.81 | ALDH1A1 (0.46) | ALDH1A1PDK1PDK2PDK3PDK4 | |
| SCHEMBL24368043 | 0.80 | EPHX1 (0.37) | ALDH1A1PDK1PDK2PDK3PDK4 | |
| SCHEMBL9288853 | 0.76 | RECQL (0.50) | ALDH1A1PDK1PDK2PDK3PDK4 | |
| SCHEMBL13923527 | 0.75 | ALDH1A1 (0.41) | ALDH1A1PDK1PDK2PDK3PDK4 | |
| SCHEMBL12565640 | 0.75 | ALDH1A1 (0.41) | ALDH1A1PDK1PDK2PDK3PDK4 | |
| SCHEMBL16072920 | 0.75 | ALDH1A1 (0.41) | ALDH1A1PDK1PDK2PDK3PDK4 | |
| SCHEMBL10264869 | 0.74 | SSTR4 (0.48) | ALDH1A1PDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200115709-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | RTCB, NSUN3, NSUN2 | ALDH1A1 3163/4885PDK1 3963/4885PDK2 4052/4885 |
| US-20200115709-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | ALDH1A1 3163/4885PDK1 3963/4885PDK2 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.